AR045178A1 - Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica - Google Patents

Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica

Info

Publication number
AR045178A1
AR045178A1 ARP040102723A ARP040102723A AR045178A1 AR 045178 A1 AR045178 A1 AR 045178A1 AR P040102723 A ARP040102723 A AR P040102723A AR P040102723 A ARP040102723 A AR P040102723A AR 045178 A1 AR045178 A1 AR 045178A1
Authority
AR
Argentina
Prior art keywords
retinoid
active
animal
human
agents
Prior art date
Application number
ARP040102723A
Other languages
English (en)
Original Assignee
Allergan Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Pharma filed Critical Allergan Pharma
Publication of AR045178A1 publication Critical patent/AR045178A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Abstract

Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composición farmacéutica de aplicación en un método para proveer un efecto terapéutico deseado, tal como tratar acné noduloquístico, a un humana o animal que posee un tracto gastrointestinal, o que posee un peso de cuerpo determinado, en donde dicho método comprende: administrar oralmente a un humano o animal una cantidad terapéuticamente efectiva de dicho componente retinoide, en donde el paso de administración es efectivo para proveer un efecto terapéutico deseado y para proveer una biodisponibilidad más constante del componente retinoide al humano o animal en presencia y ausencia de alimentos en el tracto gastrointestinal del humano o animal con respecto al empleo de isotretinoina el lugar del componente retinoide en un paso de administración oralmente idéntico. Preferentemente, la administración se realiza en forma sistémica para proveer una concentración máxima en sangre de agente retinoide activo en el humano o animal de más de 30 ng/ml, proveyendo un menor efecto secundario o, por lo menos, un efecto secundario reducido con relación al empleo de un agente retinoide de referencia.
ARP040102723A 2003-07-30 2004-07-30 Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica AR045178A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49120803P 2003-07-30 2003-07-30
US49114303P 2003-07-30 2003-07-30
US50656103P 2003-09-26 2003-09-26
US51247203P 2003-10-17 2003-10-17
US52556903P 2003-11-26 2003-11-26

Publications (1)

Publication Number Publication Date
AR045178A1 true AR045178A1 (es) 2005-10-19

Family

ID=34120126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102723A AR045178A1 (es) 2003-07-30 2004-07-30 Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica

Country Status (7)

Country Link
US (3) US20050027003A1 (es)
EP (1) EP1653942A1 (es)
AR (1) AR045178A1 (es)
AU (1) AU2004261301A1 (es)
CA (1) CA2534008A1 (es)
TW (1) TW200522935A (es)
WO (1) WO2005011668A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013157087A (ru) * 2011-06-03 2015-07-20 Аллерган, Инк. Целевая доставка ретиноидных соединений к сальным железам
EP3126858B1 (en) * 2014-04-02 2022-05-04 Sikorsky Aircraft Corporation System and method for health monitoring of electrical systems
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity
NO346299B1 (en) 2019-11-28 2022-05-30 Prores As Improved tool for remedial of lost circulation while drilling

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322438A (en) * 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5906920A (en) * 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system

Also Published As

Publication number Publication date
EP1653942A1 (en) 2006-05-10
US20050027003A1 (en) 2005-02-03
US20050026957A1 (en) 2005-02-03
TW200522935A (en) 2005-07-16
AU2004261301A1 (en) 2005-02-10
US20050026951A1 (en) 2005-02-03
WO2005011668A1 (en) 2005-02-10
CA2534008A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
US20210000761A1 (en) Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
ES2703505T3 (es) Combinación de adapaleno y peróxido de benzoilo para tratar lesiones de acné
HK1085390A1 (en) Solution for ungual and peri-ungual application and its use in preparation of a medicament treating dermatological diseases
RU2699651C1 (ru) Распыляемые носитель и композиция для местного применения, содержащие фосфатидилхолин
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
US20220110860A1 (en) Transdermal formulations
JP2023061951A (ja) 皮膚障害の処置
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
US20100015216A1 (en) Methods and materials for treating acne
BR0318343A (pt) composição tópica para administração transdérmica
AR045178A1 (es) Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica
AU2004281521B2 (en) Topical compositions comprising telmesteine for treating dermatological disorders
WO2015044763A1 (en) Valerolactam derivatives for dermal/transdermal delivery of molecules
AR067320A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias
US20200146983A1 (en) Enhanced antibiotic and drug delivery for aqueous topical applications for human and veterinary uses
RU2005140963A (ru) Лечебно-профилактическое средство "эйхлофил", его применение и способ профилактики и лечения заболеваний
JP6016085B2 (ja) 抗真菌外用組成物及び抗真菌外用組成物の適用方法
AR108793A1 (es) Composiciones que comprenden timolol y un agente antiinflamatorio
AR045177A1 (es) Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave
AR114012A1 (es) Método para proporcionar terapia de celiprolol a un paciente
AR114587A1 (es) Formulaciones de epinefrina en aerosol
AR067861A1 (es) Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivamente y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos
KR20170035916A (ko) 중증 여드름의 치료를 위한 아다팔렌 및 벤조일 퍼옥시드의 조합
AR058509A1 (es) Compuesto macrolona de eritromicina, su uso para preparar un medicamento y composicion farmaceutica que lo comprende
RU2011146671A (ru) Комбинация для профилактики и лечения эндометритов крупного рогатого скота и ее применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure